Sarah Aqel

Dr. Sarah Aqel

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 December 2023 in Biology
Verified
Journal Article
Open access
PDF file
SASarah Aqel
Sarah Aqel
NANajlaa Al-Thani
Najlaa Al-Thani
MHMohammad Zulqurnain Haider
Mohammad Zulqurnain Haider
Samar AbdelhadySamar Abdelhady
Samar Abdelhady
ATAsmaa A. Al Thani
Asmaa A. Al Thani
Abdullah A. ShaitoAbdullah A. Shaito
Abdullah A. Shaito
Traumatic brain injury (TBI) is a leading cause of mortality and long-term impairment globally. TBI has a dynamic pathology, encompassing a variety of metabolic and molecular events that occur in two phases: primary and secondary. A forceful external blow to the brain initiates the primary phase, followed by a secondary phase that involves the release of calcium ions (Ca2+) and the initiation of a cascade of inflammatory processes, including mitochondrial dysfunction, a rise in oxidative stress, activation of glial cells, and damage to the blood–brain barrier (BBB), resulting in paracellular leakage. Currently, there are no FDA-approved drugs for TBI, but existing approaches rely on delivering micro- and macromolecular treatments, which are constrained by the BBB, poor retention, off-target toxicity, and the complex pathology of TBI. Therefore, there is a demand for innovative and alternative therapeutics with effective delivery tactics for the diagnosis and treatment of TBI. Tissue engineering, which includes the use of biomaterials, is one such alternative approach. Biomaterials, such as hydrogels, including self-assembling peptides and electrospun nanofibers, can be used alone or in combination with neuronal stem cells to induce neurite outgrowth, the differentiation of human neural stem cells, and nerve gap bridging in TBI. This review examines the inclusion of biomaterials as potential treatments for TBI, including their types, synthesis, and mechanisms of action. This review also discusses the challenges faced by the use of biomaterials in TBI, including the development of biodegradable, biocompatible, and mechanically flexible biomaterials and, if combined with stem cells, the survival rate of the transplanted stem cells. A better understanding of the mechanisms and drawbacks of these novel therapeutic approaches will help to guide the design of future TBI therapies.

21 February 2024 in Irish Journal of Medical Science (1971 -)
Verified
Journal Article
Open access
PDF file
Mazhar Al ZoubiMazhar Al Zoubi
Mazhar Al Zoubi
RKRasha Al Kreasha
Rasha Al Kreasha
SASarah Aqel
Sarah Aqel
ASAhmad Saeed
Ahmad Saeed
AAAhmad Al-Qudimat
Ahmad Al-Qudimat
ASAlrayyan Private school
Alrayyan Private school
Metformin is the most prescribed oral hypoglycemic drug and is considered by many health practitioners as the first-line treatment for non-insulin-dependent diabetes mellitus (T2DM). It is used either as a monotherapy or adjuvant to other anti-hyperglycemic agents. Most of its side effects are usually mild and self-limiting. However, several studies have shown an association between the use of metformin and low vitamin B12 levels in diabetic patients. The current review aimed to provide a literature review of the current published reports on the association, the possible mechanisms, and the related individualized risk factors that might lead to this incidence. The most accepted mechanism of the effect of metformin on vitamin B12 level is related to the absorption process where metformin antagonism of the calcium cation and interference with the calcium-dependent IF-vitamin B12 complex binding to the ileal cubilin receptor. In addition, many risk factors have been associated with the impact of metformin on vitamin B12 levels in diabetic patients such as dose and duration where longer durations showed a greater prevalence of developing vitamin B12 deficiency. Male patients showed lower levels of vitamin B12 compared to females. Black race showed a lower prevalence of vitamin B12 deficiency in metformin-treated patients. Moreover, chronic diseases including T2DM, hyperlipidemia, coronary artery disease, polycystic ovary disease (PCOD), obesity, and metformin therapy were significantly associated with increased risk of vitamin B12 deficiency. Graphical abstract Metformin impacts vitamin B12 by (A) inhibiting calcium-dependent IF-B12 binding. (B) Prolonged use raises deficiency risk. (C) Males have lower B12 levels than females. (D) Black individuals show lower deficiency rates. (E) Conditions like T2DM, hyperlipidemia, coronary artery disease, PCOD, obesity, and metformin use heighten deficiency risk.

26 January 2025 in Biology
Verified
Journal Article
Open access
PDF file
SASarah Aqel
Sarah Aqel
JAJamil Ahmad
Jamil Ahmad
ISIman Saleh
Iman Saleh
AFAseela Fathima
Aseela Fathima
ATAsmaa A. Al Thani
Asmaa A. Al Thani
Abdullah A. ShaitoAbdullah A. Shaito
Abdullah A. Shaito
Neurodegenerative disorders (NDs) cause progressive neuronal loss and are a significant public health concern, with NDs projected to become the second leading global cause of death within two decades. Huntington’s disease (HD) is a rare, progressive ND caused by an autosomal-dominant mutation in the huntingtin (HTT) gene, leading to severe neuronal loss in the brain and resulting in debilitating motor, cognitive, and psychiatric symptoms. Given the complex pathology of HD, biomarkers are essential for performing early diagnosis, monitoring disease progression, and evaluating treatment efficacy. However, the identification of consistent HD biomarkers is challenging due to the prolonged premanifest HD stage, HD’s heterogeneous presentation, and its multiple underlying biological pathways. This study involves a 10-year bibliometric analysis of HD biomarker research, revealing key research trends and gaps. The study also features a comprehensive literature review of emerging HD biomarkers, concluding the need for better stratification of HD patients and well-designed longitudinal studies to validate HD biomarkers. Promising candidate wet HD biomarkers— including neurofilament light chain protein (NfL), microRNAs, the mutant HTT protein, and specific metabolic and inflammatory markers— are discussed, with emphasis on their potential utility in the premanifest HD stage. Additionally, biomarkers reflecting brain structural deficits and motor or behavioral impairments, such as neurophysiological (e.g., motor tapping, speech, EEG, and event-related potentials) and imaging (e.g., MRI, PET, and diffusion tensor imaging) biomarkers, are evaluated. The findings underscore that the discovery and validation of reliable HD biomarkers urgently require improved patient stratification and well-designed longitudinal studies. Reliable biomarkers, particularly in the premanifest HD stage, are crucial for optimizing HD clinical management strategies, enabling personalized treatment approaches, and advancing clinical trials of HD-modifying therapies.

3 August 2024 in Journal of Infection and Public Health
Verified
Journal Article
Open access
MSMohamed Sallam
Mohamed Sallam
RJRaihana Jabbar
Raihana Jabbar
LMLylu K. Mahadoon
Lylu K. Mahadoon
TETasneem J. Elshareif
Tasneem J. Elshareif
MDMariam Darweesh
Mariam Darweesh
HAHamad Al-Romaihi
Hamad Al-Romaihi
Public health threats can significantly impact mass gatherings and enhancing surveillance systems would thus be crucial. Epidemic Intelligence from Open Sources (EIOS) was introduced to Qatar to complement the existing surveillance measures in preparation to the FIFA World Cup Qatar 2022 (FWC22). This study estimated the empirical probability of EIOS detecting signals of public health relevance. It also looked at the factors responsible for discerning a moderate-high risk signal during a mass gathering event. This cross-sectional descriptive study used data collected between November 8th and December 25th, 2022, through an EIOS dashboard that filtered open-source articles using specific keywords. Triage criteria and scoring scheme were developed to capture signals and these were maintained in MS Excel. EIOS' contribution to epidemic intelligence was assessed by the empirical probability estimation of relevant public health signals. Chi-squared tests of independence were performed to check for associations between various hazard categories and other independent variables. A multivariate logistic regression evaluated the predictors of moderate-high risk signals that required prompt action. The probability of EIOS capturing a signal relevant to public health was estimated at 0.85 % (95 % confidence interval (CI) [0.82 %-0.88 %]) with three signals requiring a national response. The hazard category of the signal had significant association to the region of occurrence (χ2 (5, N = 2543) = 1021.6, p < .001). The hazard category also showed significant association to its detection during matchdays of the tournament (χ2 (5, N = 2543) = 11.2, p < .05). The triage criteria developed was able to discern between low and moderate-high risk signals with an acceptable discrimination (Area Under the Curve=0.79). EIOS proved useful in the early warning of public health threats.

22 June 2024 in Clinical Epidemiology and Global Health
Verified
Journal Article
Open access
SHSamer Hammoudeh
Samer Hammoudeh
SASarah Aqel
Sarah Aqel
FMFarha Mukthar
Farha Mukthar
PCPrem Chandra
Prem Chandra
IJIbrahim Janahi
Ibrahim Janahi

26 October 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
SASarah Aqel
Sarah Aqel
NANajlaa Al-Thani
Najlaa Al-Thani
MHMohammad Zulqurnain Haider
Mohammad Zulqurnain Haider
Samar AbdelhadySamar Abdelhady
Samar Abdelhady
ATAsmaa A. Al Thani
Asmaa A. Al Thani
Abdullah A. ShaitoAbdullah A. Shaito
Abdullah A. Shaito
Traumatic brain injury (TBI) is among the leading causes of mortality and long-term impairment globally. TBI has a dynamic pathology encompassing a variety of metabolic and molecular events that occur in two phases, primary and secondary. An external forceful blow to the brain initiates the primary phase, which is followed by a secondary phase that involves the release of calcium ions (Ca2+) and the initiation of a cascade of inflammatory processes, including mitochondrial dysfunction, rise in oxidative stress, activation of glial cells, and damage to the blood-brain barrier (BBB), resulting in paracellular leakage. There is currently no FDA-approved drug for TBI, but existing approaches rely on delivering small and macromolecular treatments, which are severely constrained by the BBB, poor retention, off-target toxicity, and complex pathology of TBI. Therefore, there is a demand for innovative and alternative therapeutics with effective delivery tactics for diagnosis and treatment of TBI. Tissue engineering and use of biomaterials is one such alternative approach. With this approach, neuronal stem cell therapy is combined with synthetically generated tissue materials such as hydrogels, self-assembling peptides, and electrospun nanofibers, which may induce neurite outgrowth, differentiation of human neural stem cells, and nerve gap bridging in TBI. This review examines tissue engineering and the use of biomaterials as potential treatments for TBI, including their synthesis, mechanisms of action, and limitations. The review also discusses challenges facing tissue engineering and biomaterial technology including survival rate of transplanted stem cells and the development of biodegradable, biocompatible, and mechanically flexible biomaterials. A better understanding of the mechanisms and drawbacks of these novel therapeutic approaches will help guide the design of future TBI therapies.